Intellia Therapeutics Inc. (NTLA)
NASDAQ: NTLAHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
NTLA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.64B
- EPS (TTM)
- -$3.17
- Dividend yield
- None
- 52-week range
- 7.95 – 28.25
- Day range
- 11.70 – 12.41
- Volume / Avg
- 8.27M / 4.09M
- Beta
- —
- Shares outstanding
- 140.13M
- Next earnings
- Nov 5, 2026
52-week range
NTLA stock today
On Oct 7, NTLA ended the session at $11.71, shedding $0.66 (5.34%), versus the S&P 500's 0.22% decline. Volume was 2.0x the average at 8.27M shares, a sign of unusually heavy trading. Shares are 58.5% below their 52-week high of $28.25, set on Oct 20, 2025 and 47.3% above the 52-week low of $7.95, near the bottom of the past year's range.
NTLA is up 30.3% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 42.7%. Intellia Therapeutics has posted a net loss over the last twelve months (EPS of -$3.17), so its P/E ratio is not meaningful. Intellia Therapeutics's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Intellia Therapeutics
Company profileIntellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated 9 (Cas9) technology for genome editing.
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CEO
- Dr. John M. Leonard M.D.
- Headquarters
- Cambridge, MA
- Employees
- 377
- IPO year
- 2016
- Website
- intelliatx.com
Analyst forecast
ForecastConsensus (20 analysts)
buy
Avg. price target
$23.11+97.35%
- Strong buy 1
- Buy 9
- Hold 6
- Sell 2
- Strong sell 2
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
- EPS estimate
- $-0.82
NTLA news
All NTLA newsIntellia Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CLDXCelldex Therapeutics Inc. | 30.43 | -1.85% | $2.39B | vs NTLA |
| NEOGNeogen Corporation | 11.68 | -2.34% | $2.55B | vs NTLA |
| IMDXInsight Molecular Diagnostics Inc. | 3.46 | +2.37% | $113.23M | vs NTLA |
| ICCCImmuCell Corporation | 9.69 | -2.81% | $88.01M | vs NTLA |
| BMRABiomerica Inc. | 1.91 | -10.75% | $8.78M | vs NTLA |
| VNRXVolitionRX Limited | 0.226 | -6.96% | $6.79M | vs NTLA |
| CDIOCardio Diagnostics Holdings Inc. | 1.96 | -2.00% | $5.80M | vs NTLA |
| TRIBTrinity Biotech plc ADR | 6.75 | -5.59% | $5.49M | vs NTLA |
Indexes, lists and sector
Intellia Therapeutics stock FAQ
What is Intellia Therapeutics's stock price today?
NTLA last traded at $11.71 as of Oct 7, 4:00 PM EDT, down 5.34% on the day. Prices are delayed at least 15 minutes.
When is Intellia Therapeutics's next earnings date?
Intellia Therapeutics is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $-0.82.
Who is Intellia Therapeutics's CEO?
Dr. John M. Leonard M.D. is the chief executive officer of Intellia Therapeutics Inc., which has about 377 employees.
What is the NTLA 52-week high?
The 52-week high for NTLA is $28.25 and the 52-week low is $7.95. The stock is currently 58.5% below its high.